GS-1156 / Gilead - LARVOL DELTA

Discovery of elunonavir (GS-1156): A metabolically stable HIV protease inhibitor that achieves a human half-life of more than two weeks without pharmacokinetic enhancement (ACS-Fall 2024) - "A Phase I clinical trial showed that elunonavir’s preclinical profile translates in humans with a half-life of more than two weeks, significantly exceeding that of any known HIV PI. These results indicate that elunonavir might address a significant gap in treatment needs, particularly for PWH with adherence challenges."

PK/PD data • Human Immunodeficiency Virus • Infectious Disease